Semaglutide
API ɗin Semaglutide
Semaglutide wani agonist mai karɓa ne na glucagon-kamar peptide-1 (GLP-1), wanda aka haɓaka don kula da nau'in ciwon sukari na 2 da kiba. An gyara tsarin don tsayayya da lalatawar enzymatic da haɓaka rabin rayuwa, Semaglutide yana ba da damar dacewa da maganin sau ɗaya a mako-mako, haɓaka haɓaka haƙuri.
MuAPI ɗin Semaglutideana samar da shi ta hanyar cikakken tsari na roba, yana kawar da haɗarin da ke tattare da tsarin maganganun halitta, kamar furotin tantanin halitta ko gurɓataccen DNA. An haɓaka gabaɗayan tsarin masana'anta kuma an inganta su a sikelin kilogram, tare da cika ƙaƙƙarfan buƙatun ingancin da aka zayyana a cikin jagorar FDA ta 2021 game da ƙaddamar da ANDA don tsaftataccen magungunan peptide roba.
Tsarin Aiki
Semaglutide yana kwaikwayon ɗan adam GLP-1, hormone incretin wanda ke taka muhimmiyar rawa a cikin metabolism na glucose. Yana aiki ta hanyoyin haɗin kai da yawa:
-
Yana ƙarfafa samar da insulina cikin yanayin da ya dogara da glucose
-
Yana hana fitar da glucagon, rage yawan fitowar glucose na hanta
-
Yana jinkirta zubar ciki, yana haifar da ingantaccen sarrafa glycemic postprandial
-
Yana rage ci da kuzari, tallafawa asarar nauyi
Sakamakon Clinical
Yawancin karatun asibiti (misali, gwajin SUSTAIN da STEP) sun nuna cewa Semaglutide:
-
Mahimmanci yana rage HbA1c da matakan glucose na plasma mai azumi a cikin masu ciwon sukari na 2
-
Yana haɓaka ɗimbin ƙima mai ɗorewa a cikin masu kiba ko masu kiba
-
Yana rage alamun haɗarin zuciya kamar hawan jini da kumburi
Tare da ingantaccen bayanin martabar aminci da fa'idodin rayuwa mai fa'ida, Semaglutide ya zama layin farko na GLP-1 RA a cikin ciwon sukari da maganin kiba. Sigar API ɗin mu tana kiyaye babban aminci na tsari da ƙarancin ƙazanta (≤0.1% ƙazantar da ba a sani ba ta HPLC), yana tabbatar da ingantaccen daidaiton magunguna.
